Clinical Trial Update: Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pilocarpine to prevent mucositis and dry mouth in patients receiving radiation therapy for head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Mucositis
• Xerostomia

Drugs mentioned

• Pilocarpine (pilocarpine)

Snippet

Sponsor: Radiation Therapy Oncology Group | Conditions: Head and Neck Cancer, Oral Complications | Phase 3 | Status: COMPLETED